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Background: Pain and agitation are common in patients after craniotomy. They can result in tachycardia,
hypertension, immunosuppression, increased catecholamine production and increased oxygen consumption.
Dexmedetomidine, an alpha-2 agonist, provides adequate sedation without respiratory depression, while facilitating
frequent neurological evaluation.
Methods/design: The study is a prospective, randomized, double-blind, controlled, parallel-group design.
Consecutive patients are randomly assigned to one of the two treatment study groups, labeled ‘Dex group’ or
‘Saline group.’ Dexmedetomidine group patients receive a continuous infusion of 0.6 μg/kg/h (10 ug/ml).
Placebo group patients receive a maintenance infusion of 0.9% sodium chloride for injection at a volume and
rate equal to that of dexmedetomidine. The mean percentages of time in optimal sedation, vital signs, various
and adverse events, the percentage of patients requiring propofol for rescue to achieve/maintain targeted
sedation (Sedation-Agitation Scale, SAS 3 to 4) and total dose of propofol required throughout the study drug
infusion are collected. The percentage of patients requiring fentanyl for additional rescue to analgesia and total
dose of fentanyl required are recorded. The effects of dexmedetomidine on hemodynamic and recovery
responses during extubation are measured. Intensive care unit and hospital length of stay also are collected.
Plasma levels of epinephrine, norepinephrine, dopamine, cortisol, neuron-specific enolase and S100-B are
measured before infusion (T1), at two hours (T2), four hours (T3) and eight hours (T4) after infusion and at the
end of infusion (T5) in 20 patients in each group.
Discussion: The study has been initiated as planned in July 2012. One interim analysis advised continuation of
the trial. The study will be completed in July 2013.
Trial registration: ClinicalTrials (NCT): ChiCTR-PRC-12002903.
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Pain and agitation are major concerns in postoperative care
of neurosurgical patients. Several studies have shown that
moderate-to-severe postoperative pain is frequent follow-
ing craniotomy [1-7]. In a recent study by Mordhorst et al.
[2], 55% of patients had moderate or severe postoperative
pain in the first 24 hours following craniotomy. This study
had a similar result to the pilot study by De Benedittis et
al. [3] in which 60% of patients experienced postoperative
pain. Agitation is common in the ICU. It has been found
that there are multiple possible causes of agitation in the
ICU setting, including the presence of existing diseases,
pain, anxiety, delirium, dressing changes, invasive proce-
dures, nursing procedures, intubation, endotracheal tubes
and surgical incisions [8,9]. Pain and agitation can cause
tachycardia, hypertension, increased catecholamine pro-
duction, increased oxygen consumption and immunosup-
pression [9,10]. Increased catecholamines have been shown
to contribute to myocardial ischemia, disturbed sleep and
catabolism [11]. Hypertension can cause an increase in
brain edema or hemorrhage, which may give rise to brain
herniation [12].
On the other hand, despite a greater awareness of pain
and agitation after craniotomy, clinicians remain reluc-
tant to administer analgesics and sedatives in patients
following craniotomy. The major concerns are the side
effects of these drugs, mainly that they reduce the clini-
cian’s ability to monitor the level of consciousness and
that they induce respiratory depression [13].
Sedation goals for neurosurgical ICU patients are to im-
prove comfort, overcome anxiety and pain, facilitate nurs-
ing care and mechanical ventilation, facilitate frequent
neurological assessments and provide sedation without
causing deleterious changes in intracranial pressure (ICP)
or cerebral perfusion pressure (CPP). An ideal sedative
agent in the ICU should be cheap, rapid in onset and off-
set and without local and systemic adverse effects. There
is no sedative agent in use that has all these ideal proper-
ties. However, dexmedetomidine, an alpha-2 agonist, pro-
vides adequate sedation without respiratory depression,
while facilitating frequent neurological evaluation.
Dexmedetomidine, a potent and highly selective
alpha-2-adrenoceptor agonist, has been available in the
United States since the end of 1999 for use in humans
as a short-term (<24 hours) medication for sedation/
analgesia in the ICU in initially intubated and mechan-
ically ventilated patients [14].
Dexmedetomidine provides dose-dependent sedation,
anxiolysis and analgesia (involving spinal and supraspinal
sites) without respiratory depression [15]. Although alpha-
2-adrenoceptors are located throughout the body, they are
present in larger concentrations in vascular smooth
muscle and in key arousal areas of the central nervous sys-
tem (CNS), such as the locus ceruleus [16]. Activation ofalpha-2-adrenoceptors in the CNS decreases centrally me-
diated sympathetic activity and induces sedation [16,17].
Activation of presynaptic alpha-2-adrenoceptors in cortical
blood vessels decreases norepinephrine release, whereas
postsynaptic alpha-2-adrenoceptors may directly increase
vascular smooth muscle tone [15-17].
Sedation with dexmedetomidine differs from sedation
with other commonly used sedatives such as propofol or
midazolam. Dexmedetomidine may induce a sedative state
similar to physiologic sleep without respiratory depression
by acting on alpha-2 receptors in the locus ceruleus
[18-20], and patients may be aroused easily with stimula-
tion and are cooperative once aroused.
In addition to its sedative effects, dexmedetomidine
has significant analgesic qualities and may significantly
reduce concomitant opioid use. Analgesia with dexme-
detomidine is mediated primarily through interaction at
alpha-2a within the spinal cord, where drug activity at-
tenuates nociceptive signal transduction. The actual
mechanism of action appears to involve an interaction
with opioid receptors and, although dexmedetomidine
alone has been documented to reduce pain, the effect
when given jointly with opioids may be additive or syn-
ergistic [21]. Dexmedetomidine provides intense anal-
gesia during the postoperative period and reduces the
total number of post-surgical patients requiring opioids
with a corresponding reduction in opioid-associated
side effects [19].
Dexmedetomidine is accompanied by virtually no re-
spiratory depression at clinically relevant doses. Despite
profound sedative properties, dexmedetomidine is associ-
ated with only limited respiratory effects, even when dosed
to plasma levels up to 15 times those normally achieved
during therapy, leading to a wide safety margin [18]. Hy-
percapnic arousal is preserved, and the apnea threshold is
actually decreased. Because dexmedetomidine has no de-
pressant effects on ventilation, its analgesic effect may
offer a significant advantage for patients at risk of respira-
tory decompensation [22].
Hemodynamic effects of dexmedetomidine may result
from both peripheral and central mechanisms. Dex-
medetomidine is the pharmacologically active dextroisomer
of medetomidine [23]. Stimulation of alpha-2 adreno-
ceptors by dexemedetomidine in pontine locus ceruleus
(LC) results in decreased firing of LC neurons secondary
to their hyperpolarization. It also has a sympatholytic ef-
fect through decreases in the concentration of norepin-
ephrine. This, in turn, decreases the blood pressure (BP)
and the heart rate (HR) [24-27]. The initial response to
rapid dexmedetomidine infusion may be a transient hyper-
tension. However, the net effect of alpha-2 adrenoceptor
action is a significant reduction in circulating catechol-
amines and a modest decrease in BP and heart rate HR.
Although hypotension has been described in patients
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to correlate with the use of a loading dose and/or pre-
existing hypovolemia [15].
A meta-analysis including 24 trials showed that
dexmedetomidine did not appear to increase risk of brady-
cardia. The risk of bradycardia was, however, significantly
higher in studies that used both a loading dose and high
maintenance doses (>0.7 ug/kg/h) than in studies that did
not use both. Risks of hypotension requiring interventions,
delirium, self-extubation, myocardial infarction, hypergly-
cemia, atrial fibrillation and mortality were not signifi-
cantly different between dexmedetomidine and traditional
sedative and analgesic agents [28].
Dexmedetomidine could be a potentially useful anes-
thetic adjuvant for neurosurgical patients [15]. Two
studies have examined its use in patients undergoing
intracranial surgery [29,30]. Both studies showed that
the addition of dexmedetomidine improves periopera-
tive hemodynamic control. In these studies, the authors
controlled arterial blood pressure with a prescribed in-
cremental dosing of anesthetics. No patient in either
study required antihypertensive medications. Dexme-
detomidine does not have a significant effect on intra-
cranial pressure [15].
Dexmedetomidine also minimizes opioid induced
muscle rigidity, decreases post-operative shivering and
has hemodynamic stabilizing effects [31]. The medica-
tion is a unique sedative in that it does not cause re-
spiratory depression and the sedated patients are easily
aroused to perform a neurological examination or to co-
operate with procedures (for example, physiotherapy,
radiology imaging) without showing irritation [32,33].
Dexmedetomedine has been reported to provide neu-
roprotective effects against ischemia in the CNS [34-38].
The S100B protein and the neuron-specific enolase (NSE)
are the most widely investigated of molecular markers in
patients with severe head injury, stroke or subarachnoid
hemorrhage (SAH). The concentration of these markers
has been shown to increase in the cerebrospinal fluid
(CSF) as well as in the serum [39-43]. In addition, in pa-
tients with SAH the course of the S100B concentration
has been shown to correlate with neurologic deficits and
outcome [44,45].
The aim of the present work is to evaluate the safety
and efficacy of dexmedetomidine for prophylactic anal-
gesia and sedation in delayed extubation patients after
craniotomy. The primary hypothesis is that prophylactic
use of dexmedetomidine will increase the percentage of
time in optimal sedation.
Methods/design
The present study is a prospective, single-center, ran-
domized, double-blind, placebo-controlled, two-arm trial
in patients with delayed extubation after craniotomy.Study setting and population
The study setting is the neurosurgical ICU, Beijing
Tiantan Hospital, Capital Medical University, Beijing,
China.
All patients after intracranial surgery with delayed
extubation admitted to our ICU are screened daily for
study eligibility. Patients are deemed eligible for this
study if they are ≥18-years-old, present with motor re-
sponses to external stimuli in the Glasgow Coma Scale
(GCS-M) equal or higher than five in two hours (time




 HR less than 50 bpm
 Systolic BP less than 90 mm Hg
 Acute myocardial infarction
 Second or third degree atrioventricular block
 Need of continuous infusions of vasopressor before
the start of study drug infusion
 Consciousness disorders or epilepsy before
intracranial surgery
 Pre-existent dysphagia and cough reflex difference
 Emergency operation
 Readmitted to ICU after randomization to the study
 Enrolled in another trial
 Pregnant or lactating women
Ethical aspects and informed consent
When a patient is identified as eligible for the study, im-
mediate contact will be made with the 24-hour on-call
study coordinator, who will confirm eligibility. Delayed
extubation patients after craniotomy are often unable to
provide consent until they improve. The attending phys-
ician will introduce the family to the study coordinator.
The physician will make sure the family knows the cre-
dentials of the study coordinator, and say that this per-
son is going to discuss a research program that is being
conducted, and that this person is qualified to do so.
The study coordinator will take the family to a place
where they can talk confidentially. Every relevant aspect
of the project will be described. The study coordinator
will stop frequently, ask if there are any questions, and
request that the family repeat back in their own words
what is being discussed, to make sure they understand.
The study coordinator will explain that there is a pos-
sibility that the patient may experience pain, agitation,
and delirium,and, if so, the patient could become worse.
The coordinator will say that there is a new alpha-2
agonist that provides adequate sedation without respira-
tory depression, while facilitating frequent neurological
evaluation. He will explain that in a small percentage
of patients, dexmedetomidine could cause bradycardia,
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advantages of using or not using dexmedetomidine will
be described. The study coordinator will be especially
careful to assure the family that they are free to decline
consent without consequences and that they can with-
draw consent at any time without impact on treatment.
Family members will be provided with contact informa-
tion for the study coordinator, local co-investigator and
the local Ethical Committee. Written consent will be
obtained in the presence of a witness.
A register is kept of all patients evaluated for inclusion
and of patients who withdraw from the study. The latter
are clinically followed up without their data being ana-
lyzed in the study.
The study protocol and consent forms were approved
by the Institutional Review Board of Beijing Tiantan
Hospital Affiliated to Capital Medical University (approval
number KY2012-006-02) and by the Chinese Clinical Trial
Registry (ChiCTR-PRC-12002903). The Beijing Tiantan
Hospitals’ Institutional Review Board gave positive advice
for the addition of their ICU as the study site.Data collected at study entry
At baseline, data on demographic characteristics and the
history of past illnesses of the patients are obtained. The
surgical site, operation time, intraoperative medication,
the input liquid quantity, and the amount of bleeding
and urine are recorded. The Acute Physiology and
Chronic Health Evaluation II score (APACHE II) and
Glasgow Coma Scale (GCS) are calculated.Randomization, double-blind and allocation concealment
The study has a prospective, randomized, double-blind,
controlled, parallel-group design. Consecutive patients
are randomly assigned to one of the two treatment
study groups, labeled ‘Dex group’ or ‘Saline group.’
Randomization is based on a computer generated ran-
dom digits table and follows a concealed process using
sealed and numbered envelopes that allocate the patient
to either of the two arms of the study. Patients may be
randomized into this study only once unless they were
discharged from the hospital and were re-admitted be-
yond 180 days of the first enrollment. The study does
not allow cross-overs and, if any occur, they will be
reported as protocol violations.
Experimental drug and placebo with the same charac-
ter are prepared by a pharmacist. Patients and all study
personnel except the investigative pharmacist are blind
to treatment assignment. The details of the series are
unknown to any of the investigators and are contained
in a set of opaque and sealed envelopes, each bearing on
the outside only the number.Trial interventions
All patients are randomized 1:1 to receive dexme-
detomidine or placebo infusion. Dexmedetomidine group
patients receive a continuous infusion of 0.6 μg/kg/h (10
ug/ml). Placebo group patients receive a maintenance infu-
sion of 0.9% sodium chloride for injection at a volume and
rate equal to that of dexmedetomidine. The patient’s level
of sedation will be assessed using the Sedation-Agitation
Scale (SAS) per hour after starting the study drug infusion.
Any patient >5 on the SAS will be given rescue propofol
in 0.5 mg/kg bolus or infusion doses 0.5 to 2 mg/kg/h
until the attaining SAS 3 or 4. Fentanyl will be given in
0.05 mg increments to treat pain as needed.
Duration of the intervention
The allocated intervention is continued until any of the
following criteria is met:
 A maximum of 24 hours on the study infusion
protocol
 30 minutes after extubation
 ICU discharge
The intervention must be emergency stopped when
the following occurs:
 HR <50 bpm after atropine in 0.25 mg bolus
 Systolic BP <90 mmHg after hydroxyethyl starch
infusion 250 ml/0.5 h




Our current primary endpoint is the mean percentages
of time in optimal sedation (SAS of 3 or 4).
Secondary endpoints
The percentage of patients requiring propofol for rescue
to achieve/maintain targeted sedation (SAS 3 or 4) and
total dose of propofol required throughout the study
drug infusion are collected. The percentage of patients
requiring fentanyl for additional rescue to analgesia and
total dose of fentanyl required are recorded.
Secondary endpoints also include vital signs and various
and adverse events. Vital signs are recorded every hour
throughout the procedure (BP, HR, respiratory rate (RR),
and SpO2) .Adverse events include hypotension, hyperten-
sion, bradycardia, tachycardia, airway obstruction, apnea,
epilepsy, cerebral hemorrhage or infarction and conscious-
ness disorders (GCS-M <5).
The effects of dexmedetomidine on hemodynamic and
recovery responses during extubation are measured. BP,
HR, RR, and SpO2 are recorded one minute before
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nutes after extubation. ICU and hospital length of stay
(LOS) are also collected.
Plasma levels of epinephrine, norepinephrine, dopamine,
cortisol, NSE and S100-B are measured before infusion
(T1), two hours (T2), four hours (T3) and eight hours
(T4) after infusion and end of infusion (T5) in 20 patients
each group.
Current sample size justification
Primarily, we expect the frequency of the patient’s agita-
tion to decrease and a reduction of pain after dexme-
detomidine infusion in delayed extubation patients after
craniotomy. In our previous studies, the baseline fre-
quency of agitation and pain in delayed extubation
patients after craniotomy was 30% and the mean per-
centage of time in optimal sedation was 88%. It is
expected that the mean percentages of time in optimal
sedation would increase to 95% after dexmedetomidine
infusion. Using the Power and Sample Size Calculation
program, we will need to study 72 experimental subjects
and 72 control subjects to be able to reject the null hy-
pothesis that the population means of the experimental
and control groups are equal with a probability (power)
of 0.8. The Type I error probability with testing this null
hypothesis is 0.05.
Statistical analysis
All analyses will be according to the intention-to-treat
principle, that is, all randomized patients will be analyzed
in the groups to which they were originally allocated and
will be blinded to treatment assignment. Baseline charac-
teristics will be summarized by carrying out univariate
analyses. Categorical variables will be presented as num-
bers and percents, percentages, and analyzed by the χ2-
test. Continuous variables will be checked for normal dis-
tribution and presented as mean and standard deviation
or median and interquartile range as appropriate. Com-
parison of continuous variables will be performed using
Student’s t-test for normally distributed variables and the
Mann–Whitney U test for non-normally distributed vari-
ables. Plasma levels of epinephrine, norepinephrine, dopa-
mine, cortisol, NSE and S100-β, and BP, HR, RR and SpO2
will be analyzed by repeated measure analysis of variance
(ANOVA). All tests of significance will be at the 5% sig-
nificance level and two-sided. Analyses will be conducted
using SPSS 17.0.
Discussion
A significant difference in the safety and/or efficacy end-
points will provide important evidence for optimizing
intracranial surgery patient sedation. Also, a neutral re-
sult will provide important insight, as this would mean
that more studies are needed to evaluate the safety andefficacy of dexmedetomidine for prophylactic analgesia
and sedation in patients after craniotomy.
Trial status
The study has been initiated as planned in July 2012. One
interim analysis advised continuation of the trial. The
study will be completed in July 2013.
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